Zomedica (NYSEAMERICAN:ZOM) Raised to “Strong-Buy” at Noble Financial

Zomedica (NYSEAMERICAN:ZOM) was upgraded by equities researchers at Noble Financial to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

Zomedica Price Performance

NYSEAMERICAN:ZOM opened at $0.12 on Monday. The firm has a market cap of $120.24 million, a P/E ratio of -2.05 and a beta of 1.06. Zomedica has a one year low of $0.12 and a one year high of $0.23.

Institutional Trading of Zomedica

An institutional investor recently raised its position in Zomedica stock. Price T Rowe Associates Inc. MD grew its stake in Zomedica Corp. (NYSEAMERICAN:ZOM) by 41.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 948,300 shares of the company’s stock after purchasing an additional 276,100 shares during the period. Price T Rowe Associates Inc. MD owned approximately 0.10% of Zomedica worth $139,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 8.95% of the company’s stock.

Zomedica Company Profile

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.